News

Total operating expenses decreased $107,869 or 2.2% vs. the prior year. Operating loss for the fiscal year was $349,490 vs. an operating loss of$602,279 for the prior year.

The new data from the phase III PLATO study showed that AstraZeneca’s BRILINTA (ticagrelor) provided reduction of cardiovascular (CV) events than clopidogrel (9.02% vs 10.65%, p=0.0025 a 16%

Boston Scientific has declared a two-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and

Repligen has announced the publication of research that identifies histone deacetylase 3 (HDAC 3) as an enzyme target for therapeutic intervention in Friedreich’s ataxia. Reportedly, the research findings

The Drugs Controller General of India (DCGI) has issued guidelines for grant of WHO-GMP Certificate of Pharmaceutical Product (CoPP) by the CDSCO offices, starting October 1. DCGI has

Aesica’s Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs

Icagen has initiated the proof-of-concept study for ICA-105665 in patients with photosensitive epilepsy. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been

Pfizer Oncology will initiate a global, phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced

Vical has presented encouraging results from animal studies of a peptide-based cancer vaccine formulated with the Vaxfectin adjuvant. The study demonstrates the adjuvant’s ability to enhance immune responses